NASDAQ:OGI Organigram (OGI) Stock Price, News & Analysis $1.07 -0.04 (-3.60%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.09 +0.02 (+1.87%) As of 03/25/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Organigram Stock (NASDAQ:OGI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organigram alerts:Sign Up Key Stats Today's Range$1.06▼$1.1450-Day Range$0.99▼$1.7352-Week Range$0.96▼$2.91Volume612,170 shsAverage Volume907,594 shsMarket Capitalization$135.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewOrganigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Read More… Remove Ads Organigram Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreOGI MarketRank™: Organigram scored higher than 14% of companies evaluated by MarketBeat, and ranked 898th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Organigram.Read more about Organigram's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Organigram are expected to grow in the coming year, from ($0.19) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organigram is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organigram is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganigram has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Organigram's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.52% of the float of Organigram has been sold short.Short Interest Ratio / Days to CoverOrganigram has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Organigram has recently increased by 25.58%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganigram does not currently pay a dividend.Dividend GrowthOrganigram does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.52% of the float of Organigram has been sold short.Short Interest Ratio / Days to CoverOrganigram has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Organigram has recently increased by 25.58%, indicating that investor sentiment is decreasing significantly. News and Social Media4.0 / 5News Sentiment1.28 News SentimentOrganigram has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Organigram this week, compared to 1 article on an average week.Search Interest2 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Organigram to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organigram insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.09% of the stock of Organigram is held by insiders.Percentage Held by InstitutionsOnly 34.63% of the stock of Organigram is held by institutions.Read more about Organigram's insider trading history. Receive OGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter. Email Address OGI Stock News HeadlinesOrganigram Unveils Bold New Brand Identity Reflecting Market Leadership Position in Canada and Growing International PresenceMarch 26 at 6:00 AM | businesswire.comOrganigram Announces Results of Annual and Special Meeting, including Shareholder Approval of Name Change to Organigram Global Inc.March 24 at 8:30 PM | businesswire.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.March 26, 2025 | Porter & Company (Ad)Organigram Is A Small-Cap BargainFebruary 23, 2025 | seekingalpha.comOrganigram Holdings Inc. (OGI): A Bull Case TheoryFebruary 18, 2025 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Royalty Pharma (RPRX), Waters (WAT) and OrganiGram Holdings (OGI)February 12, 2025 | markets.businessinsider.comOrganigram price target lowered to C$3 from C$4.25 at Alliance GlobalFebruary 11, 2025 | markets.businessinsider.comOrganigram reports Q1 revenue C$42.7M vs. C$36.5M last yearFebruary 11, 2025 | markets.businessinsider.comSee More Headlines OGI Stock Analysis - Frequently Asked Questions How have OGI shares performed this year? Organigram's stock was trading at $1.61 at the beginning of the year. Since then, OGI stock has decreased by 33.5% and is now trading at $1.07. View the best growth stocks for 2025 here. How were Organigram's earnings last quarter? Organigram Holdings Inc. (NASDAQ:OGI) posted its earnings results on Tuesday, February, 11th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. Organigram had a negative trailing twelve-month return on equity of 8.59% and a negative net margin of 31.69%. When did Organigram's stock split? Organigram's stock reverse split on Friday, July 7th 2023. The 1-4 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. Who are Organigram's major shareholders? Top institutional investors of Organigram include Tidal Investments LLC (1.37%), Renaissance Technologies LLC (0.72%), Arrowstreet Capital Limited Partnership (0.57%) and AdvisorShares Investments LLC (0.57%). How do I buy shares of Organigram? Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organigram own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include i3 Verticals (IIIV), Ford Motor (F), Lucid Group (LCID), Trade Desk (TTD), Finance of America Companies (FOA), NVIDIA (NVDA) and Company Calendar Last Earnings2/11/2025Today3/25/2025Next Earnings (Estimated)5/13/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OGI CIK1620737 Webwww.organigram.ca Phone(844) 644-4726FaxN/AEmployees860Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,390,000.00 Net Margins-31.69% Pretax Margin-31.53% Return on Equity-8.59% Return on Assets-6.54% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio1.85 Sales & Book Value Annual Sales$166.12 million Price / Sales0.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book0.58Miscellaneous Outstanding Shares126,217,000Free Float126,103,000Market Cap$135.05 million OptionableOptionable Beta1.01 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:OGI) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.